Co-founded by Nobel Prize scientist Craig Mello (RNAi discoverer), Phio leverages advanced gene silencing technology to enhance immune cell effectiveness against tumor cells without requiring specialized drug delivery systems. The company is transitioning from discovery to development with recent leadership strengthening to support regulatory engagement and clinical advancement.
Cyborg Score Rationale
Early-stage asset with encouraging Phase 1b data showing 85% pathological response at highest dose; however, ultra-low market cap (~$11.6M), minimal cash runway, and high execution risk are significant concerns. Stock volatility reflects both the potential of the technology and substantial clinical/commercial uncertainties.
Top Insights
Phase 1b PH-762 trial shows 85% pathological response in highest dose cohort with no dose-limiting toxicities—rare positive safety/efficacy signal for early-stage oncology
INTASYL self-delivering siRNA platform targets cancer immunosuppression without complex drug delivery, providing potential competitive advantage in crowded immuno-oncology space
Recent leadership appointments in CFO, regulatory, and program development roles signal pivot toward clinical advancement and commercial readiness for PH-762
Company has raised capital for cGMP manufacturing with goal of commercially viable drug production by late 2026, indicating progress toward regulatory pathway
Named Competitors
Checkpoint Inhibitors — Established immuno-oncology class with PD-1/PD-L1 therapies